Hidradenitis Suppurativa Carries Heavy Comorbidity Burden
There is a substantial burden, unawareness, and undertreatment of several systemic comorbidities—particularly cardiovascular and psychiatric—in patients with HS.
All articles by Brandon May
Types of Data Compromised in Breaches of Protected Health Information Identified
In this study, 71% of the breaches compromised sensitive demographic or
financial information that may be used for fraudulent purposes.
Liraglutide Improves Glycemic Control in Children and Adolescents With T2D
Daily liraglutide, in addition to metformin and insulin, reduces HbA1c and improves glycemic control in young patients with type 2 diabetes.
Cardiorenal Disease Is the Most Common CVD Manifestation in Patients With T2D
Cardiorenal disease is commonly the first cardiovascular disease manifestation in patients with type 2 diabetes.
Potential Therapeutic Efficacy of Imeglimin in Targeting Mitochondrial Bioenergetics in T2D
Researchers at EASD 2019 presented current data and ongoing clinical trial designs for the first-in-class experimental drug, imeglimin, for the treatment of type 2 diabetes.
ADO09 Confers Better Glucose Control, Slower Gastric Emptying Than Insulin Lispro in T1D
ADO09, a coformulation of amylin analog pramlintide and A21G human insulin, is superior to insulin lispro for reducing postprandial blood glucose in patients with type 1 diabetes.
ACP Releases Policy Statement on DOI, COI Management for Clinical Guideline Development
The American College of Physicians endorses the necessity of a comprehensive process for disclosure of potential conflicts of interest to ensure the integrity of clinical guidelines and guidance statements.
Gram-Negative Bacilli SSTIs on the Rise in Patients With Diabetes
A number of upward epidemiologic trends and associated risk factors for mortality seen in patients with diabetes.
Alirocumab Safety Profile Similar Regardless of MI, Ischemic Stroke Status
In patients with prior myocardial infarction (MI)/ischemic stroke, treatment with alirocumab is associated with a reduction in low-density lipoprotein cholesterol (LDL-C), as well as reductions in lipoprotein(a), apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C), according to study results published in the Journal of Clinical Lipidology. In addition, efficacy and safety results were similar in patients…
AHA/HFS Release Scientific Statement on Concomitant Type 2 Diabetes and Heart Failure
The American Heart Association and Heart Failure Society released a joint scientific statement summarizing the effects of type 2 diabetes management on heart failure outcomes.
Next post in Type 2 Diabetes
